Abstract
Outcome assessment in osteoarthritis (OA) clinical trials is dependent on the use of valid, reliable, and responsive measurement procedures. The measurement of antirheumatic drug efficacy currently lacks international standardization, and current guidelines are not in complete agreement. There remains an urgent need to agree on a core set of outcome measures for hip OA, knee OA, hand OA, and generalized OA clinical trials. A degree of harmonization has been achieved in the measurement of adverse events using the WHO and COSTART systems. However, different methods of eliciting adverse events result in different event rate scores. The optimum method of assessing beneficial and adverse events in OA clinical trials has yet to be elucidated but is the subject of ongoing research and discussion.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bellamy N. Introduction. In:Musculoskeletal Clinical Metrology. Dordrecht: Kluwer Academic Publishers; 1993:3–4.
Taylor D. A table for the degree of involvement in chronic arthritis. Can Med Assoc J. 1937;36:608–10.
Bellamy N. The evolution of assessment techniques. In: Musculoskeletal Clinical Metrology. Dordrecht: Kluwer Academic Publishers; 1993:5–9.
Bellamy N. Future perspective. In: Musculoskeletal Clinical Metrology. Dordrecht: Kluwer Academic Publishers; 1993:253–68.
WHO. Guidelines for the clinical investigation of drugs used in rheumatic diseases, European Drug Guidelines, Series 5, World Health Organization, Regional Office for Europe, Copenhagen, European League Against Rheumatism. March 1985:1–4.
Guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drugs (adults and children). US Department of Health and Human Services. Public Health Services, Food and Drug Administration, April 1988:12–15.
Lequesne M, Brandt K, Bellamy N, et al. Guidelines for the testing slow acting drugs in osteoarthritis. J Rheumatol. 1994;21(Suppl. 41):65–71.
Bellamy N. Osteoarthritis. In: Musculoskeletal Clinical Metrology. Dordrecht: Kluwer Academic Publishers; 1993:169–76.
Bellamy N. WOMAC Osteoarthritis Index - A User’s Guide. London, Canada: Victoria Hospital; 1995.
Lequesne M. Indices of severity and disease activity for osteoarthritis. Semin Arthritis Rheum. 1991;20(Suppl. 2):48–54.
Bellamy N. Health status instruments and functional indices. In: Musculoskeletal Clinical Metrology. Dordrecht: Kluwer Academic Publishers; 1993:77–101.
Drieser R-L, Maheu E, Guillou GB, Caspard H, Grouin J-M. Validation of an algofunctional index for osteoarthritis of the hand. Revue du Rhumatisme, English Edition, Joint Bone, Spine Diseases. 1995;6(Suppl. 1):43S–53S.
Bellamy N, Buchanan WW. Clinical evaluation in the rheumatic diseases. In: Koopman WJ, ed. Arthritis and Allied Conditions, 13th edn. Baltimore: Williams & Wilkins; 1996: [in press].
Hawker G, Melfi C, Paul J, Green R, Bombardier C. Comparison of a generic (SF-36) and a disease specific (WOMAC) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol. 1995;22:1193–6.
Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Ann Rheum Dis. 1981;40:75–8.
Rosenbloom D, Brooks P, Bellamy N, Buchanan W. Osteoarthritis. In: Clinical Trials in the Rheumatic Diseases. A Selected Critical Review. New York: Praeger Publishers; 1985:19–69.
Peloso PMJ. The validation of the patient oriented symptoms index for measuring patient side effects in rheumatology clinical trials. M.Sc. Thesis, University of Toronto, Toronto, Canada, 1994.
COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms, 3rd edn. US Dept of Commerce, National Technical Information Service, Springfield, Virginia, 1989.
WHO. The WHO Adverse Reaction Dictionary. WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 1990.
Fries JF, Spitz PW,Williams CA, Bloch DA, Sing G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum. 1990;33:121–30.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Bellamy, N. (1997). Measuring Beneficial and Adverse Events in Osteoarthritis Clinical Trials. In: Rainsford, K.D. (eds) Side Effects of Anti-Inflammatory Drugs IV. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5394-2_5
Download citation
DOI: https://doi.org/10.1007/978-94-011-5394-2_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6269-5
Online ISBN: 978-94-011-5394-2
eBook Packages: Springer Book Archive